Targeted therapies in combination with chemotherapy in non-small cell lung cancer

David H. Johnson, Alan Sandler, Bruce Johnson, Rogerio Lilenbaum, Alex Adjei, Glenwood Goss

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic chemotherapy in advanced non-small cell lung cancer have yielded disappointing results. The reasons underlying these spectacular failures are not always fully understood, but certainly the lack of careful patient selection is a major contributing factor. In addition, recent preclinical and clinical studies indicate that antagonism may exist between the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy primarily in tumor cells with wild-type EGFR. By contrast, tumor cells harboring somatic mutations in EGFR experience massive apoptosis when exposed to the EGFR tyrosine kinase inhibitors. Therefore, in theory, mutant tumor cells should exhibit enhanced cell kill when treated with concomitant chemotherapy and EGFR tyrosine kinase inhibitors akin to what is observed with chemotherapy and trastuzumab in breast cancer. Clinical data from the recently completed TRIBUTE trial support the latter possibility. Ideally, future studies of EGFR tyrosine kinase inhibitors and other targeted drugs will use careful patient selection criteria based on well-characterized and validated predictive markers. However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number14
DOIs
StatePublished - Jul 15 2006

Fingerprint

Combination Drug Therapy
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Patient Selection
Drug Therapy
Therapeutics
Neoplasms
Pharmaceutical Preparations
Biomarkers
Clinical Trials
Apoptosis
Breast Neoplasms
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeted therapies in combination with chemotherapy in non-small cell lung cancer. / Johnson, David H.; Sandler, Alan; Johnson, Bruce; Lilenbaum, Rogerio; Adjei, Alex; Goss, Glenwood.

In: Clinical Cancer Research, Vol. 12, No. 14, 15.07.2006.

Research output: Contribution to journalArticle

Johnson, David H. ; Sandler, Alan ; Johnson, Bruce ; Lilenbaum, Rogerio ; Adjei, Alex ; Goss, Glenwood. / Targeted therapies in combination with chemotherapy in non-small cell lung cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 14.
@article{6335d9ce37fb4d01954a93a0ee0c3521,
title = "Targeted therapies in combination with chemotherapy in non-small cell lung cancer",
abstract = "With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic chemotherapy in advanced non-small cell lung cancer have yielded disappointing results. The reasons underlying these spectacular failures are not always fully understood, but certainly the lack of careful patient selection is a major contributing factor. In addition, recent preclinical and clinical studies indicate that antagonism may exist between the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy primarily in tumor cells with wild-type EGFR. By contrast, tumor cells harboring somatic mutations in EGFR experience massive apoptosis when exposed to the EGFR tyrosine kinase inhibitors. Therefore, in theory, mutant tumor cells should exhibit enhanced cell kill when treated with concomitant chemotherapy and EGFR tyrosine kinase inhibitors akin to what is observed with chemotherapy and trastuzumab in breast cancer. Clinical data from the recently completed TRIBUTE trial support the latter possibility. Ideally, future studies of EGFR tyrosine kinase inhibitors and other targeted drugs will use careful patient selection criteria based on well-characterized and validated predictive markers. However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development.",
author = "Johnson, {David H.} and Alan Sandler and Bruce Johnson and Rogerio Lilenbaum and Alex Adjei and Glenwood Goss",
year = "2006",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-06-0095",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Targeted therapies in combination with chemotherapy in non-small cell lung cancer

AU - Johnson, David H.

AU - Sandler, Alan

AU - Johnson, Bruce

AU - Lilenbaum, Rogerio

AU - Adjei, Alex

AU - Goss, Glenwood

PY - 2006/7/15

Y1 - 2006/7/15

N2 - With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic chemotherapy in advanced non-small cell lung cancer have yielded disappointing results. The reasons underlying these spectacular failures are not always fully understood, but certainly the lack of careful patient selection is a major contributing factor. In addition, recent preclinical and clinical studies indicate that antagonism may exist between the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy primarily in tumor cells with wild-type EGFR. By contrast, tumor cells harboring somatic mutations in EGFR experience massive apoptosis when exposed to the EGFR tyrosine kinase inhibitors. Therefore, in theory, mutant tumor cells should exhibit enhanced cell kill when treated with concomitant chemotherapy and EGFR tyrosine kinase inhibitors akin to what is observed with chemotherapy and trastuzumab in breast cancer. Clinical data from the recently completed TRIBUTE trial support the latter possibility. Ideally, future studies of EGFR tyrosine kinase inhibitors and other targeted drugs will use careful patient selection criteria based on well-characterized and validated predictive markers. However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development.

AB - With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic chemotherapy in advanced non-small cell lung cancer have yielded disappointing results. The reasons underlying these spectacular failures are not always fully understood, but certainly the lack of careful patient selection is a major contributing factor. In addition, recent preclinical and clinical studies indicate that antagonism may exist between the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy primarily in tumor cells with wild-type EGFR. By contrast, tumor cells harboring somatic mutations in EGFR experience massive apoptosis when exposed to the EGFR tyrosine kinase inhibitors. Therefore, in theory, mutant tumor cells should exhibit enhanced cell kill when treated with concomitant chemotherapy and EGFR tyrosine kinase inhibitors akin to what is observed with chemotherapy and trastuzumab in breast cancer. Clinical data from the recently completed TRIBUTE trial support the latter possibility. Ideally, future studies of EGFR tyrosine kinase inhibitors and other targeted drugs will use careful patient selection criteria based on well-characterized and validated predictive markers. However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development.

UR - http://www.scopus.com/inward/record.url?scp=33746884660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746884660&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0095

DO - 10.1158/1078-0432.CCR-06-0095

M3 - Article

C2 - 16857827

AN - SCOPUS:33746884660

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -